Quark Pharmaceuticals Inc., which develops RNA interference drugs, withdrew initial public offering plans to raise up to $20 million.
The company reportedly did not obtain favorable terms and could raise additional private funding, according to a Dow Jones VentureWire story.
No comments:
Post a Comment